Comparison of the Efficacy and Safety of Different Doses of Linaclotide for Patients with Chronic Constipation: A Meta-Analysis and Bayesian Analysis

Table 1

Baseline characteristics of the eligible studies.

Study	Country	Centers	Diagnostic criteria for CC	Total number	Female (%)	Dose of linaclotide (μg)	Treatment time	Outcomes
Fukudo1, 2018	Japan	NA	Rome III	382	83.25	62.5, 125, 250, 500	2 w	CSBM responder; SBM responder; global assessment of relief; abnormal bowel habits improvement; abdominal symptoms relief
Lembo, 2010	USA	57	Rome II	310	91.86	75, 150, 300, 600	4 w	CSBM responder; SBM responder; abnormal bowel habits improvement
Fukudo2, 2018	Japan	39	Rome III	181	82.32	500	4 w	CSBM responder; SBM responder; global assessment of relief; abnormal bowel habits improvement; abdominal symptoms relief
Lacy, 2015	USA; Canada	141	Rome II	483	91.5	145, 290	12 w	CSBM responder; global assessment of relief; abnormal bowel habits improvement; abdominal symptoms relief
Schoenfeld, 2017	USA	105	Rome III	1223	77	72, 145	12 w	CSBM responder; global assessment of relief
Lembo, 2011	USA; Canada	212	Rome II	1276	88.64	145, 290	12 w	CSBM responder; global assessment of relief; abdominal symptoms relief
Brenner, 2020	USA	71	Rome III	252	59.9	145,290	8 w	SBM responder